In contrast to [213Bi]Bi-PSMA-617 (1.2 GBq), [225Ac]Ac-PSMA-617 (7.4 MBq) delivered higher tumor doses (42.1 vs. 7.6 SvRBE5), also resulting in significantly higher salivary gland exposure (17.0 vs. 9.7 SvRBE5). This evidence concerns the gene FOLH1 and neoplasm.